Protect Generic Drugs in India

Defend affordable drug treatment in India

Health groups call on German drugmaker Bayer to cancel the suit against the Indian government and domestic drug company Cipla in order to protect affordable drug treatment. The organizations fear that the fate of generics in India may hinge on this case and that thousands of Indians will die without affordable pharmaceuticals.

=> India: High court ruling strikes a blow for patient's rights

=> Bayer CEO: Cancer Drug is Only For Westerners Who Can Afford It

=> Bayer plea against Natco dismissed, compulsory license upheld

=> Cancer drug prices: US pressure on Indian government

=> India: compulsory license from Bayer for cancer drug

=> India: Supreme Court rejects Bayer's appeal for patent linkage

more info on Nexavar patents and developing costs

=> Bayer beaten in Indian court over patent law

=> Health groups: Defend affordable drug treatment in India

=> Open letter to BAYER: Trial-related deaths in India